Can This Patient Safely Take Terbinafine?
No, this 47-year-old man should not take terbinafine with his current liver enzyme elevations (AST 56, ALT 45), even for just two weeks. The British Association of Dermatologists guidelines explicitly state that systemic terbinafine is not recommended in patients with pre-existing liver disease, and baseline liver function tests should be normal before initiating therapy 1.
Why This Matters
The patient's transaminases are elevated above normal ranges (typically AST/ALT <40 U/L). While these elevations are mild (approximately 1.1-1.4 times the upper limit of normal), they indicate underlying hepatic dysfunction. Terbinafine carries a risk of serious hepatotoxicity, which occurs predominantly in patients with pre-existing liver disease 1.
The Evidence on Hepatotoxicity Risk
- Although terbinafine demonstrates minimal hepatic toxicity in most patients, rare cases of serious hepatotoxicity have been documented 1
- The incidence of serious adverse events is 0.04% overall, but this risk increases substantially in patients with baseline liver abnormalities 1
- Recent case reports document severe drug-induced liver injury from terbinafine, including cholestatic patterns requiring months for recovery 2, 3, 4
- Hepatotoxicity can occur even with short-term use (as brief as 2-4 weeks) 2, 5
What Should Be Done Instead
Step 1: Investigate the Liver Enzyme Elevation
Before considering any systemic antifungal therapy, determine why this patient has elevated transaminases:
- Assess alcohol consumption history (use AUDIT-C questionnaire if needed) 6
- Screen for viral hepatitis (HBV, HCV)
- Evaluate for non-alcoholic fatty liver disease (calculate FIB-4 or NAFLD Fibrosis Score) 6
- Review all current medications for potential hepatotoxic agents
- Consider metabolic syndrome components
Step 2: Treatment Options Once Liver Status Clarified
If liver enzymes normalize:
- Terbinafine 250 mg daily can be prescribed (6 weeks for fingernails, 12-16 weeks for toenails) 1
- Repeat baseline liver function tests before starting
- Monitor liver enzymes during treatment, especially if therapy exceeds 1 month
If liver disease is confirmed or enzymes remain elevated:
- Use topical therapy instead: Amorolfine 5% lacquer once-twice weekly for 6-12 months 1
- Alternative topical: Ciclopirox 8% lacquer daily for up to 48 weeks 1
- These topical agents avoid systemic hepatic exposure and are specifically recommended when systemic therapy is contraindicated 1
If systemic therapy is absolutely necessary despite liver concerns:
- Consider itraconazole as an alternative (though it also requires hepatic monitoring) 1
- Fluconazole may be used but similarly requires baseline and ongoing liver function monitoring 1
Critical Pitfalls to Avoid
- Don't assume "just two weeks" is safe – hepatotoxicity has been reported with short-duration therapy 2, 5
- Don't ignore mild transaminase elevations – these patients are precisely the population at higher risk for terbinafine-induced liver injury 1
- Don't start terbinafine without baseline normal liver function tests – this violates guideline recommendations for safe prescribing 1
The AST/ALT Pattern
The patient's AST:ALT ratio is 1.24 (56/45), which is slightly elevated. While this ratio can provide diagnostic clues about liver disease etiology, any elevation above normal ranges contraindicates terbinafine initiation until the underlying cause is identified and resolved 1.
The bottom line: Postpone terbinafine therapy, investigate the liver enzyme abnormalities, and use topical antifungals in the interim if treatment cannot wait.